Translational development phase in personalised medicine a focus group on in silico preclinical models

Shortly after the successful focus group to explore the industry perspective on preclinical research, the second working session on June 1st assessing the translational development phase looked at in silico models for personalised medicine. During this second meeting, the group, composed of five experts from the field, explored some common bottlenecks and potential solutions. The importance of high-quality data collection and sharing was debated, as well as the relevance of model validation for ensuring reliable results and regulation-related issues.

As in the previous focus group, the outcome of the meeting will support the development of recommendations in the personalised medicine research domain and will be further discussed in a dedicated workshop titled “Recommendations for more robust and reproducible preclinical research in personalised medicine” scheduled for Wednesday, September 1st.